




EASL CONGRESS

Barcelona Spain
27–30 May **2026**



LIST OF ACCEPTED LATE BREAKING ABSTRACTS

#EASLCongress

easlcongress.eu

Abstract number: LB26-5002

Presentation number: LBP-020

Title: A global Delphi consensus to define chronic liver disease severity: replacing cirrhosis with a stage-based model

Presentation type: Poster presentation

Presenting author: Aleksander Krag

Abstract number: LB26-5003

Presentation number: OS-106

Title: Safety and efficacy of pemafibrate (K-808), a selective peroxisome proliferator-activated receptor alpha modulator, in patients with primary biliary cholangitis: twelve-week data from the randomized, placebo-controlled, PEMA-PBC dose-finding study

Presentation type: Oral presentation

Presenting author: Gideon M. Hirschfield

Abstract number: LB26-5012

Presentation number: LBP-040

Title: Functional cure rate in chronic hepatitis B virus infected participants receiving elebsiran and pegylated interferon alfa: final results from the phase 2 ENSURE study

Presentation type: Poster presentation

Presenting author: Grace Lai-Hung Wong

Abstract number: LB26-5013

Presentation number: LBP-041

Title: HSK31679, a thyroid hormone receptor beta agonist, improves histological outcomes in Asian patients with MASH and F2–F3 fibrosis: a 52-week phase 2b randomized, double-blind, placebo-controlled trial

Presentation type: Poster presentation

Presenting author: Feng Xue

Abstract number: LB26-5037

Presentation number: LBP-022-YI

Title: Single-dose of a novel monoclonal anti-HBV antibody (HepB mAb19) demonstrates sustained HBsAg suppression beyond 48 weeks: interim results from first-in-human phase I RUHBV1 and SAMBA trials

Presentation type: Poster presentation

Presenting author: Han Ngoc Le

Abstract number: LB26-5040

Presentation number: OS-107

Title: Linafexor in UDCA-inadequate PBC: A phase 2 trial of a pulsatile FXR agonist

Presentation type: Oral presentation

Presenting author: Xiao Xiao

Abstract number: LB26-5041

Presentation number: LBP-012

Title: High rate and sustained HBsAg loss achieved with HT-101 plus HT-102 combination therapy in HBeAg-negative, nucleos(t)ide analogue-suppressed patients: ongoing off-treatment results from a multicenter Ib/IIa study

Presentation type: Poster presentation

Presenting author: Jinlin Hou

Abstract number: LB26-5046

Presentation number: LBO-002

Title: Plasma exchange with albumin 5% significantly increases 90-day overall survival in acute-on-chronic liver failure: topline results of the APACHE trial

Presentation type: Oral presentation

Presenting author: Javier Fernández

Abstract number: LB26-5048

Presentation number: LBP-028-YI

Title: Preventing vertical transmission of hepatitis B virus in Democratic Republic of Congo by combining birth-dose vaccine and tenofovir: a randomized double-blind placebo-controlled trial

Presentation type: Poster presentation

Presenting author: Patrick Ngimbi

Abstract number: LB26-5050

Presentation number: LBP-024

Title: In F0-F1 and F2-F3 MASH, $\geq 5\%$ weight loss (WL) significantly lowers VCTE and ELF independent of biopsy fibrosis improvement; resmetirom and not placebo reduction of ELF and VCTE are associated with biopsy improvement of fibrosis, independent of WL

Presentation type: Poster presentation

Presenting author: Rohit Loomba

Abstract number: LB26-5056

Presentation number: LBP-014

Title: Safety, tolerability, pharmacokinetics and pharmacodynamics of an orally innovative GalNAc-conjugated thyroid hormone receptor-beta agonist (Kylo-0603) in healthy volunteers: a multiple ascending dose study

Presentation type: Poster presentation

Presenting author: Xingjiang Hu

Abstract number: LB26-5060

Presentation number: LBP-021

Title: 24-week safety and efficacy of brelovitug monotherapy for the treatment of chronic hepatitis D: data from phase 2b of AZURE-1

Presentation type: Poster presentation

Presenting author: Tatyana Kushner

Abstract number: LB26-5075

Presentation number: LBO-006

Title: Efficacy and safety of Volixibat, an IBAT inhibitor, in patients with primary sclerosing cholangitis and moderate-to-severe pruritus: results of the VISTAS trial

Presentation type: Oral presentation

Presenting author: Cynthia Levy

Abstract number: LB26-5076

Presentation number: LBO-003

Title: Tune-401: a first-in-class epigenetic silencer of HBV demonstrates deep and durable antiviral activity in the phase 1b/2a proof of concept Tune-401-001 study

Presentation type: Oral presentation

Presenting author: Edward J. Gane

Abstract number: LB26-5077

Presentation number: LBO-005-YI

Title: The combination of senolytic drugs, dasatinib plus quercetin, reduces liver fibrosis in metabolic dysfunction-associated steatohepatitis: a phase 2 randomized double-blind placebo controlled study: the TRUTH study

Presentation type: Oral presentation

Presenting author: Mijra Koning

Abstract number: LB26-5091

Presentation number: LBP-008

Title: longitudinal multi-omics reveals regenerative programs and predictive plasma signatures in human liver regeneration

Presentation type: Poster presentation

Presenting author: Martin Cornillet

Abstract number: LB26-5092

Presentation number: LBP-039

Title: Survodutide reduces steatosis and fibrosis in a MASH human liver spheroid model through direct glucagon receptor agonism

Presentation type: Poster presentation

Presenting author: Francisco Verdeguer

Abstract number: LB26-5093

Presentation number: LBP-044

Title: Integrated serum proteomics and N-glycoproteomics for non-invasive biomarkers in primary biliary cholangitis

Presentation type: Poster presentation

Presenting author: Dong Zhao

Abstract number: LB26-5096
Presentation number: LBP-003
Title: Home-based exercise and motivational programme before and after liver transplantation (EXALT): a multicentre randomised, controlled trial
Presentation type: Poster presentation
Presenting author: Matthew Armstrong

Abstract number: LB26-5099
Presentation number: LBP-019-YI
Title: Data for action: real-world hepatitis c virus and human immunodeficiency virus co- and hepatitis c virus mono-infection epidemiology to inform strategic hepatitis c virus elimination in south africa
Presentation type: Poster presentation
Presenting author: Bongani Khanyi

Abstract number: LB26-5101
Presentation number: LBP-006-YI
Title: A single-cell multiome atlas reveals tumor microenvironment subtypes and immune regulatory programs in perihilar cholangiocarcinoma
Presentation type: Poster presentation
Presenting author: Yanjie Chen

Abstract number: LB26-5127
Presentation number: LBP-009
Title: Synthetic data generation by artificial intelligence predicts clinical outcomes in untreated and Bulevirtide-treated patients with chronic hepatitis Delta
Presentation type: Poster presentation
Presenting author: Saverio D'amico

Abstract number: LB26-5130
Presentation number: LBO-004-YI
Title: Safety, pharmacokinetics, and clinical activity of HRX215 after hepatectomy due to colon carcinoma metastases: interim results from pilot cohort of a 1b/2a clinical trial
Presentation type: Oral presentation
Presenting author: Tillmann Taube

Abstract number: LB26-5133
Presentation number: LBP-036
Title: Pemvidutide treatment led to fibrosis regression after 24 weeks in patients with metabolic dysfunction-associated steatohepatitis: quantitative digital pathology analysis from the IMPACT phase 2b, multicenter, randomized, placebo-controlled trial
Presentation type: Poster presentation
Presenting author: Shaheen Tomah

Abstract number: LB26-5134
Presentation number: LBO-001
Title: A phase 2b/3 trial of saroglitazar in primary biliary cholangitis (EPICS III)
Presentation type: Oral presentation
Presenting author: Raj Vuppalanchi

Abstract number: LB26-5136
Presentation number: LBP-042
Title: Safety, tolerability, sustained hepatitis B surface antigen reduction and HBsAg clearance ratio in chronic hepatitis B patients treated with long-term BW-20507
Presentation type: Poster presentation
Presenting author: Man-Fung Yuen

Abstract number: LB26-5137
Presentation number: LBP-015
Title: Thybetador, a potent and selective THR- β agonist: results from a phase 1 first-in-human study in healthy volunteers and participants with elevated LDL-C
Presentation type: Poster presentation
Presenting author: Xiangwei Hua

Abstract number: LB26-5147
Presentation number: LBP-023
Title: Real-world outcomes in patients with primary biliary cholangitis who initiated elafibranor treatment with baseline alkaline phosphatase levels between 1 \times to 1.67 \times the upper limit of normal
Presentation type: Poster presentation
Presenting author: Cynthia Levy

Abstract number: LB26-5148
Presentation number: LBP-018
Title: Improvements in fatigue in patients with primary biliary cholangitis treated with elafibranor: patient-reported outcome measurement information system fatigue short form 7a (PFSF 7a) data from the phase III ELATIVE[®] trial
Presentation type: Poster presentation
Presenting author: David E. Jones

Abstract number: LB26-5151
Presentation number: LBP-016
Title: Immunogenetic predictors of hepatitis D virus infection progression in Uzbekistan: implications for a national screening strategy
Presentation type: Poster presentation
Presenting author: Zebiniso Sofiya Ismailova

Abstract number: LB26-5152

Presentation number: LBP-017

Title: Longitudinal analysis of routine laboratory data prospectively identifies clinically significant hepatic fibrosis from the general population, outperforming standard fibrosis scores: validation from the LiveWell multi-modal screening study

Presentation type: Poster presentation

Presenting author: Timothy Jobson

Abstract number: LB26-5159

Presentation number: LBP-004-YI

Title: Real-world validation of elafibranor in UDCA non-responders previously treated with OCA or fibrates — results from the ELEVATE-PBC study

Presentation type: Poster presentation

Presenting author: Alessandra Bonfichi

Abstract number: LB26-5164

Presentation number: LBP-027

Title: ARO-INHBE demonstrates clinically meaningful reductions in liver fat as monotherapy and in combination with low-dose tirzepatide in adults with obesity

Presentation type: Poster presentation

Presenting author: Rinki Murphy

Abstract number: LB26-5165

Presentation number: LBP-043

Title: First evidence of elimination and inactivation of cccDNA in liver biopsies collected from patients with chronic hepatitis B treated with PBGENE-HBV

Presentation type: Poster presentation

Presenting author: Man-Fung Yuen

Abstract number: LB26-5173

Presentation number: LBP-033

Title: Elafibranor treatment results in rapid reductions in biochemical markers and symptom burden in real-world practice: interim results from the prospective, non-interventional ELFINITY phase IV global study in patients with primary biliary cholangitis

Presentation type: Poster presentation

Presenting author: Jörn M. Schattenberg

Abstract number: LB26-5176

Presentation number: LBP-038

Title: A novel trientine tetrahydrochloride formulation administered once-a-day for people living with Wilson disease: results from a phase 2 study

Presentation type: Poster presentation

Presenting author: Emmanouil Tsochatzis

Abstract number: LB26-5179
Presentation number: LBP-002
Title: Sirolimus attenuates liver fibrosis in advanced chronic liver disease: a phase II randomised controlled trial
Presentation type: Poster presentation
Presenting author: Aloysious Aravinthan

Abstract number: LB26-5186
Presentation number: LBP-011
Title: Pharmacological effects of apixaban and edoxaban in patients with liver cirrhosis
Presentation type: Poster presentation
Presenting author: Montserrat Fraga Christinet

Abstract number: LB26-5188
Presentation number: LBP-026
Title: Hepatic recompensation is associated with sustained transplant-free survival in primary biliary cholangitis decompensated cirrhosis: an international multicenter study from the Global-PBC study group
Presentation type: Poster presentation
Presenting author: Adrielly Martins

Abstract number: LB26-5192
Presentation number: LBP-007
Title: Comparative study of the efficacy and safety of systemic glucocorticosteroids on liver enzyme activity in patients with autoimmune hepatitis without liver cirrhosis
Presentation type: Poster presentation
Presenting author: Volodymyr Cherniavskiy

Abstract number: LB26-5196
Presentation number: LBP-005
Title: Treatment of hepatitis C in pregnancy with Sofosbuvir/Velpatasvir: interim results from the STORC study
Presentation type: Poster presentation
Presenting author: Catherine Chappell

Abstract number: LB26-5197
Presentation number: LBP-034-YI
Title: Real-world experience with seladelpar in primary biliary cholangitis: first results from the Italian RESTART-PBC study
Presentation type: Poster presentation
Presenting author: Francesca Terracciani

Abstract number: LB26-5201
Presentation number: LBP-030

Title: Rotational thromboelastometry-guided transfusion strategy versus conventional management in difficult-to-treat acute variceal bleeding in ACLF: a randomised controlled trial

Presentation type: Poster presentation

Presenting author: Madhumita Premkumar

Abstract number: LB26-5202

Presentation number: LBP-013

Title: A phase Ib multiple dose ascending study of HH-006 in treatment-naïve participants with chronic hepatitis B virus infection

Presentation type: Poster presentation

Presenting author: Jinlin Hou

Abstract number: LB26-5204

Presentation number: LBP-010

Title: Safety, tolerability, pharmacokinetics, and pharmacodynamics of DA-1726, an oxyntomodulin analogue, in a higher-dose phase 1 cohort with exploratory noninvasive liver assessment

Presentation type: Poster presentation

Presenting author: Chris Fang

Abstract number: LB26-5206

Presentation number: LBP-032

Title: Denifanstat and resmetirom combination therapy rapidly decreased atherogenic lipids in healthy adults in Phase 1 open-label trial

Presentation type: Poster presentation

Presenting author: Mary E. Rinella

Abstract number: LB26-5207

Presentation number: LBP-037

Title: Seladelpar leads to decreases in serum proteins associated with PBC disease severity: proteomic analysis from the pivotal RESPONSE trial

Presentation type: Poster presentation

Presenting author: Michael Trauner

Abstract number: LB26-5209

Presentation number: LBP-031

Title: AHB-137 monotherapy elicits high functional cure rates and sustained DNA suppression in treatment-naïve chronic hepatitis B participants: results from an ongoing phase II study

Presentation type: Poster presentation

Presenting author: Yunqing Qiu

Abstract number: LB26-5224

Presentation number: LBP-025

Title: Once-monthly efimosfermin alfa in participants with metabolic dysfunction-associated steatohepatitis with F2/F3 fibrosis: post hoc results from a 24-week, randomized, double-blind, placebo-controlled, phase 2 trial

Presentation type: Poster presentation

Presenting author: Rohit Loomba

Abstract number: LB26-5225

Presentation number: LBP-035

Title: Scalable bioreactor production of functional iPSC-derived hepatic microtissues demonstrates unprecedented therapeutic efficacy in a preclinical model of acute liver failure

Presentation type: Poster presentation

Presenting author: Dilyana TODOROVA

Abstract number: LB26-5234

Presentation number: LBP-029

Title: Weight loss-independent Glucagon effect led to rapid, clinically significant reductions in MASH severity, including steatosis and liver stiffness, during a 48-week randomized controlled trial of dual agonist DD01

Presentation type: Poster presentation

Presenting author: Mazen Nouredin

Abstract number: LB26-5239

Presentation number: LBP-001

Title: Primary care liver fibrosis detection pathway in people with type 2 diabetes: results from the PRELUDE1 prospective, pragmatic, electronic health record-embedded, parallel-arm cohort study

Presentation type: Poster presentation

Presenting author: William Alazawi